Johnathan W. Hamrick, PharmD; Diane Nykamp, PharmD
- 2月 24 週三 201607:52
[US pharmacist]Drug-induced Bleeding 藥物導致的出血
Johnathan W. Hamrick, PharmD; Diane Nykamp, PharmD
- 4月 03 週五 201522:09
Vitamin D Supplementation for Pain
US Pharm. 2015;40(3):43-46.
ABSTRACT: Vitamin D, a fat-soluble vitamin found in few natural food sources, is synthesized in human skin after sun exposure. Up to 80% of patients in U.S. healthcare facilities are deficient in vitamin D, which is thought to contribute to a wide range of health issues. Vitamin D has long been utilized in combination with calcium to improve bone health and reduce the risk of fractures. Vitamin D supplementation has been linked to the prevention of high blood pressure, cancer, and other diseases. Recent research also points to a possible association between vitamin D deficiency and chronic pain.
- 2月 26 週四 201505:26
[US pharmacist]Hypertension 101: A Review of JNC 8
ABSTRACT: The Eighth Joint National Committee report (JNC 8) was released in 2013 and is now serving as a guideline to therapy for patients with hypertension. An expert panel developed JNC 8, and primary literature was used to form nine recommendations regarding the treatment of hypertension as well as blood pressure goals for various patient populations. This continuing education (CE) article will address how JNC 8 was developed and will provide the recommendations made by the expert panel. This CE will also compare JNC 8 to other guidelines used for the treatment of hypertension.
Hypertension (HTN), or high blood pressure, is one of the most common medical conditions affecting the U.S. population; about one in three U.S. adults is diagnosed with hypertension, yet only 47% of them are within guideline-defined goals.1
- 1月 25 週日 201509:37
[US pharmacist]Drug Therapy for Endometriosis-Associated Pain
US Pharm. 2015;40(1):HS13-HS17.
ABSTRACT: Endometriosis is a debilitating condition in women that results in chronic painful symptoms and infertility. Endometriosis, which is caused by the presence of endometrial tissues outside the uterus, occurs predominantly in women of reproductive age. However, adolescents and postmenopausal women also can develop it. Symptoms include pelvic pain, lower-back pain, dysmenorrhea, and dyspareunia. Treatment consists of drugs, surgery, or both, depending upon the severity of the symptoms. Combined hormonal contraceptives, progestins, gonadotropin-releasing hormone analogues, danazol, and nonsteroidal anti-inflammatory drugs are current pharmacologic options for pain management. These agents are effective for alleviation of pain, but they fail to prevent disease recurrence. Consequently, other therapeutic alternatives are needed for long-term benefit.
- 12月 17 週三 201404:43
[US pharmacist]New Changes in Pregnancy and Lactation Labeling 懷孕與授乳分級的新標示
ABSTRACT: On May 29, 2008, the FDA issued a proposed rule aimed at revising current regulations on the pregnancy,labor and delivery, and nursing mother sections of prescribing information. The aim of the new labeling format is to provide sufficient information to pregnant and breastfeeding patients and their healthcare providers when prescribing and counseling about medication. Following approval, the new regulations will eliminate the commonly known pregnancy letter categories and create pregnancy and lactation sections, each of which will contain fetal risk summary, clinical considerations, and data subsections.
On May 29, 2008, the FDA issued a proposed rule aimed at revising current regulations pertaining to the pregnancy, labor and delivery, and nursing mother sections of the prescribing information for prescription drugs and biologic products.1 Initiation of this amendment was prompted by the FDA’s goal to provide women and their healthcare providers with sufficient information when deciding which medications to prescribe in pregnant and breastfeeding patients.2 Improved regulations to ensure safe and effective medication use during pregnancy are essential, considering that about half of all pregnancies are unexpected, leading to unintended drug exposure.
- 11月 26 週三 201408:40
[US pharmacist]Treatment of Alcohol Withdrawal Syndrome 酒精戒斷症狀的治療
US Pharm. 2014;39(11):38-41.
Edward DeSimone, RPh, PhD, FAPhA
Professor of Pharmacy Sciences
Creighton University
School of Pharmacy and Health Professions
Omaha, Nebraska - See more at: http://www.uspharmacist.com/content/d/feature/c/51657/#sthash.ObvhDY4o.dpuf
- 5月 20 週二 201409:22
[US pharmacist]The Role of Probiotics in Children With Gastrointestinal Disease 益生菌在兒童腸道疾病中扮演的角色
US Pharm. 2014;39(5):22-26.
- 2月 12 週三 201405:55
[US pharmacist]Epidermal Growth Factor Receptor Inhibitors and Skin Rash EGFR抑制劑與皮膚狀況
- 1月 27 週一 201407:39
[US pharmacist]Drug-Induced Neurologic Conditions 藥物引起的神經學症狀
US Pharm. 2014;39(1):47-51.
- 1月 14 週二 201404:32
[US pharmacist]Long-Term Consequences of Chronic Proton Pump Inhibitor Use 長期使用離子泵浦抑制劑的結果
US Pharm. 2013;38(12):38-42.
ABSTRACT: Proton pump inhibitors (PPIs), available with or without a prescription, are commonly used for the treatment of acid-related disorders. Despite their ease of availability and common use, PPIs can have severe side effects. The long-term consequences of chronic PPI use include the potential increased risk of hypocalcemia, hypomagnesemia, Clostridium difficile infections, and pneumonia. Community pharmacists are poised to provide evidence-based recommendations and educate patients about the benefits and risks associated with chronic PPI use.
醫藥類 (14)